NCT02191228View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

February 28, 2010

Conditions
Renal Insufficiency
Interventions
DRUG

Linagliptin - single dose

DRUG

Linagliptin - Multiple dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02191228 - Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function | Biotech Hunter | Biotech Hunter